New Plenity patient prescriptions increased 3.5-fold within the first three weeks of the national media campaign launch
The company has projected $58 million in net revenue in this first full launch year 2022
BOSTON, March 17 (Bernama-BUSINESS WIRE) — Gelesis (NYSE: GLS), the maker of Plenity, announced preliminary results from its broad awareness media campaign that debuted January 31, 2022. Within the first three weeks, the company saw a 3-fold increase in web traffic and 3.5-fold increase in the number of individuals seeking a new prescription compared to previous months when supply was limited. Gelesis anticipates that its 2022 net product revenue will be approximately $58 million in its first year of full launch, reaffirming guidance the company issued earlier this year.
